Evonik at the MedTec 2013
Biostable or bioresorbable, implants or medical devices, Evonik Industries will be exhibiting at the forthcoming MedTec Europe in Stuttgart, where it will once again feature its custom solutions for the medical technology industry.
FDA approval for spinal cage implants
In numerous European and Asian countries, VESTAKEEP® PEEK polymers have been approved for direct contact with the human body, for both short-term applications and in long-term implants. Now, for the first time, the U.S. Food and Drug Administration has approved a spinal column implant made of VESTAKEEP® PEEK. The associated pre-market notification 510(k) has been successfully issued and will make it far easier in the future for medical device manufacturers to get approval.
Evonik’s polyetheretherketone (PEEK) is not only biocompatible and biostable; indeed, its good processability is a persuasive reason to use it. VESTAKEEP® PEEK lends itself well to injection molding and cutting processes in production and supports freedom of design in the development of new implant technologies.
Portfolio: VESTAMID® Care and TROGAMID® Care product series is broadened
The Care product series covers a broad portfolio of high-performance polymers specially designed for medical technology applications. Evonik is constantly expanding its portfolio with basic polymers and compounds.
All Care series products are biocompatible and satisfy the requirements of USP Class VI. Evonik offers a selection of custom product solutions that are geared to the technical needs of its customers. The VESTAMID® and TROGAMID® products are used in a variety of applications in medical technology: catheters for vessel therapy, surgical instruments, and stopcocks for infusion equipment, among other uses.
Visit us February 26–28, 2013, at the MedTec Europe in Stuttgart, Germany, Hall 1, Booth M62! We look forward to having an interesting discussion with you.
Evonik, the creative industrial group from Germany, is one of the world’s leading specialty chemicals companies. Profitable growth and a sustained increase in the value of the company form the heart of our strategy. Our activities focus on the key megatrends health and nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.